1. Home
  2. LAC vs SNDX Comparison

LAC vs SNDX Comparison

Compare LAC & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lithium Americas Corp.

LAC

Lithium Americas Corp.

HOLD

Current Price

$4.54

Market Cap

2.0B

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$18.12

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAC
SNDX
Founded
2023
2005
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
LAC
SNDX
Price
$4.54
$18.12
Analyst Decision
Hold
Strong Buy
Analyst Count
7
13
Target Price
$6.14
$38.69
AVG Volume (30 Days)
11.5M
1.5M
Earning Date
05-14-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
11.56
EPS
N/A
N/A
Revenue
N/A
$172,352,000.00
Revenue This Year
N/A
$107.19
Revenue Next Year
N/A
$41.88
P/E Ratio
N/A
N/A
Revenue Growth
N/A
627.84
52 Week Low
$2.47
$8.59
52 Week High
$10.52
$25.59

Technical Indicators

Market Signals
Indicator
LAC
SNDX
Relative Strength Index (RSI) 43.84 39.71
Support Level $4.40 $14.53
Resistance Level $5.40 $22.40
Average True Range (ATR) 0.33 0.79
MACD -0.10 -0.00
Stochastic Oscillator 19.04 38.78

Price Performance

Historical Comparison
LAC
SNDX

About LAC Lithium Americas Corp.

Lithium Americas Corp is a Canadian-based resource and materials company focused on developing, building and operating lithium deposits and chemical processing facilities. The company also holds investments in Green Technology Metals Limited (GT1) and Ascend Elements, Inc. (Ascend Elements), and exploration properties in the U.S. and Canada. The company's flagship asset is Thacker Pass, a sedimentary-based lithium deposit located in the McDermitt Caldera in Humboldt County, in northern Nevada (Thacker Pass or the Project). The company operates in only one operating segment and one geographical segment.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: